key: cord-0735125-6awhy1ut
authors: Jimenez‐Cauhe, J.; Ortega‐Quijano, D.; Carretero‐Barrio, I.; Suarez‐Valle, A.; Saceda‐Corralo, D.; Moreno‐Garcia del Real, C.; Fernandez‐Nieto, D.
title: Erythema multiforme‐like eruption in patients with COVID‐19 infection: clinical and histological findings
date: 2020-05-09
journal: Clin Exp Dermatol
DOI: 10.1111/ced.14281
sha: 23ae2b946395e71d241b934ebc2be3d1c5bc9115
doc_id: 735125
cord_uid: 6awhy1ut

Cutaneous manifestations in patients with COVID‐19 infection are being increasingly reported. Several patterns have been described since the initial report by Recalcati,(1) including erythematous maculo‐papular,(1) urticarial,(1,2) chickenpox‐like,(1,3) purpuric peri‐flexural,(4) transient livedo reticularis,(5) and acro‐ischemic or chilblain‐like lesions.(6,7) Herein we report the observation a new pattern with erythema multiforme‐like lesions in 4 hospitalized patients with COVID‐19 infection. All of them were women, and the mean age was 66.75 years (range 58 – 77). The mean time period between the onset of COVID‐19 symptoms to the appearance of cutaneous lesions was 19.5 days (range 16 – 24). One patient developed the skin rash during hospitalization. The remaining 3 patients had been previously discharged after clinical, analytical and radiologic improvement, and negativization of COVID‐19 PCR test. These 3 patients returned to the Emergency department consulting for skin rashes 6, 7 and 4 days after discharge, respectively. Laboratory tests at the time of skin lesions showed worsening of one or more parameters, compared to those at the time of discharge (CRP, D‐dimer and lymphocyte count). However, none of the patients presented recurrence of clinical symptoms of COVID‐19. Microbiological studies were performed in 2 patients, excluding other infectious diseases (Table 1). In all patients, skin lesions begun as erythematous papules in upper trunk, that progressively turned to erythemato‐violaceous patches with a dusky center, and a pseudo‐vesicle in the middle. Typical target lesions were observed in two patients. Lesions were markedly coalescing in the back, and then spread to the face and limbs within 1 week, without involvement of palms and soles (Figure 1). Three patient had their oral cavity examined, showing palatal macules and petechiae. Histological examination was similar in all patients, revealing a normal basket‐weave stratum corneum, and mild to moderate spongiosis in epidermis. The dermis showed dilated vessels filled with neutrophils, extravasation of red blood cells, and lymphocytic perivascular and interstitial infiltrate. Basal vacuolar changes with interface dermatitis was observed in 1 patient, and lymphocytic exocytosis in another (Figure 2). All patients were treated with systemic corticosteroids with progressive resolution of the skin lesions within 2‐3 weeks. We are facing challenging times in Dermatology. New information and cutaneous manifestations possibly related to COVID‐19 are emerging every day. Further studies are needed to evaluate whether these lesions are associated with the virus, the drug intake or any other conditions. Erythema multiforme (EM) is linked to infectious agents in 90% of the cases, while drug‐associated EM is reported in less than 10% of cases. Herpes simplex virus (HSV) and Mycoplasma pneumoniae are the main agents, but other viruses have been reported, such as Adenovirus, Coxsackie, Parvovirus B19.(8) We suggest that this EM‐like or target‐like exanthem might be another pattern of exanthem associated with COVID‐19 infection. Recent articles also report targetoid lesions in exanthems of patients with COVID‐19 infection.(9,10) In addition, the presence of pseudo‐vesicles and enanthem are two clues that suggest an infectious cause rather than a drug reaction. However, we cannot positively exclude the involvement of the various drugs administered to the patients. This is a first observation that will require further investigations.

the mean age was 66.75 years (range 58 -77). The mean time period between the onset of COVID-19 symptoms to the appearance of cutaneous lesions was 19.5 days (range 16 -24). One patient developed the skin rash during hospitalization. The remaining 3 patients had been previously discharged after clinical, analytical and radiologic improvement, and negativization of COVID-19 PCR test. These 3 patients returned to the Emergency department consulting for skin rashes 6, 7 and 4 days after discharge, respectively. Laboratory tests at the time of skin lesions showed worsening of one or more parameters, compared to those at the time of discharge (CRP, D-dimer and lymphocyte count). However, none of the patients presented recurrence of clinical symptoms of COVID-19. Microbiological studies were performed in 2 patients, excluding other infectious diseases (Table 1 ). In all patients, skin lesions begun as erythematous papules in upper trunk, that progressively turned to erythemato-violaceous patches with a dusky center, and a pseudo-vesicle in the middle. Typical target lesions were observed in two patients. We are facing challenging times in Dermatology. New information and cutaneous manifestations possibly related to COVID-19 are emerging every day. Further studies are needed to evaluate whether these lesions are associated with the virus, the drug intake or any other conditions. Erythema multiforme (EM) is linked to infectious agents in 90% of the cases, while drug-associated EM is reported in less than 10% of cases.

Herpes simplex virus (HSV) and Mycoplasma pneumoniae are the main agents, but other viruses have been reported, such as Adenovirus, Coxsackie, Parvovirus B19. 8 We suggest that this EM-like or target-like exanthem might be another pattern of exanthem associated with COVID-19 infection. Recent articles also report targetoid lesions in exanthems of patients with COVID-19 infection. 9, 10 In addition, the presence of pseudo-vesicles and enanthem are two clues that suggest an infectious cause rather than a drug reaction.

However, we cannot positively exclude the involvement of the various drugs administered to the patients. This is a first observation that will require further investigations. 

This article is protected by copyright. All rights reserved 

Cutaneous manifestations in COVID-19: a first perspective

Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies

Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome

Reply to "COVID-19 can present with a rash and be mistaken for Dengue": Petechial rash in a patient with COVID-19 infection

A Dermatologic Manifestation of COVID-19: Transient Livedo Reticularis

Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak

Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients

Accepted Article This article is protected by copyright. All rights reserved 8

Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist

SARS-CoV-2 infection presenting as a febrile rash

Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection

This article is protected by copyright. All rights reserved The authors would like to thank all the health workers that have been fighting against COVID-19 in Spain.